Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
Disorders of calcium and phosphorus metabolism are associated with significant morbidity and mortality in patients with advanced chronic kidney disease. These patients typically require oral phosphate binders to maintain phosphorus homeostasis, but the choice of which among several agents to use has been actively investigated and debated. Recent debate has been polarized between those who favor calcium-based binders for their proven efficacy and relatively low cost and those who favor sevelamer for its putative beneficial effects on inflammatory biomarkers and vascular calcification. This review summarizes the current state of the art of prescribing phosphate binders, ranging from large-scale clinical trials to focused mechanistic studies, and proposes that the available evidence does not conclusively prove the relative superiority of any one binder.
Novak
James E
JE
Division of Nephrology & Hypertension, Henry Ford Health System, Detroit, Michigan 48202, USA. jnovak2@hfhs.org
Szczech
Lynda A
LA
D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D028044:Phosphate-Binding Proteins / Q000627:therapeutic use*; D010710:Phosphates / Q000378:metabolism*; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006435:Renal Dialysis; D012307:Risk Factors
D028044:Phosphate-Binding Proteins; D010710:Phosphates